Cargando…

Antiviral activity of nano-monocaprin against Phi6 as a surrogate for SARS-CoV-2

The COVID-19 pandemic involving SARS-CoV-2 has raised interest in using antimicrobial lipid formulations to inhibit viral entry into their host cells or to inactivate them. Lipids are a part of the innate defense mechanism against pathogens. Here, we evaluated the use of nano-monocaprin (NMC) in inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorinolu, Adeola Julian, Mamun, M. Mustafa, Vadarevu, Hemapriyadarshini, Vivero-Escoto, Juan L., Vejerano, Eric P., Munir, Mariya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685086/
https://www.ncbi.nlm.nih.gov/pubmed/36422769
http://dx.doi.org/10.1007/s10123-022-00300-6
_version_ 1784835427678552064
author Sorinolu, Adeola Julian
Mamun, M. Mustafa
Vadarevu, Hemapriyadarshini
Vivero-Escoto, Juan L.
Vejerano, Eric P.
Munir, Mariya
author_facet Sorinolu, Adeola Julian
Mamun, M. Mustafa
Vadarevu, Hemapriyadarshini
Vivero-Escoto, Juan L.
Vejerano, Eric P.
Munir, Mariya
author_sort Sorinolu, Adeola Julian
collection PubMed
description The COVID-19 pandemic involving SARS-CoV-2 has raised interest in using antimicrobial lipid formulations to inhibit viral entry into their host cells or to inactivate them. Lipids are a part of the innate defense mechanism against pathogens. Here, we evaluated the use of nano-monocaprin (NMC) in inhibiting enveloped (phi6) and unenveloped (MS2) bacteriophages. NMC was prepared using the sonochemistry technique. Size and morphology analysis revealed the formation of ~ 8.4 ± 0.2-nm NMC as measured by dynamic light scattering. We compared the antiviral activity of NMC with molecular monocaprin (MMC) at 0.5 mM and 2 mM concentrations against phi6, which we used as a surrogate for SARS-CoV-2. The synthesized NMC exhibited 50% higher antiviral activity against phi6 than MMC at pH 7 using plaque assay. NMC inactivated phi6 stronger at pH 4 than at pH 7. To determine if NMC is toxic to mammalian cells, we used MTS assay to assess its IC(50) for HPDE and HeLa cell lines, which were ~ 203 and 221 µM, respectively. NMC may be used for prophylactic application either as a drop or spray since many viruses enter the human body through the mucosal lining of the nose, eyes, and lungs.
format Online
Article
Text
id pubmed-9685086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-96850862022-11-28 Antiviral activity of nano-monocaprin against Phi6 as a surrogate for SARS-CoV-2 Sorinolu, Adeola Julian Mamun, M. Mustafa Vadarevu, Hemapriyadarshini Vivero-Escoto, Juan L. Vejerano, Eric P. Munir, Mariya Int Microbiol Research The COVID-19 pandemic involving SARS-CoV-2 has raised interest in using antimicrobial lipid formulations to inhibit viral entry into their host cells or to inactivate them. Lipids are a part of the innate defense mechanism against pathogens. Here, we evaluated the use of nano-monocaprin (NMC) in inhibiting enveloped (phi6) and unenveloped (MS2) bacteriophages. NMC was prepared using the sonochemistry technique. Size and morphology analysis revealed the formation of ~ 8.4 ± 0.2-nm NMC as measured by dynamic light scattering. We compared the antiviral activity of NMC with molecular monocaprin (MMC) at 0.5 mM and 2 mM concentrations against phi6, which we used as a surrogate for SARS-CoV-2. The synthesized NMC exhibited 50% higher antiviral activity against phi6 than MMC at pH 7 using plaque assay. NMC inactivated phi6 stronger at pH 4 than at pH 7. To determine if NMC is toxic to mammalian cells, we used MTS assay to assess its IC(50) for HPDE and HeLa cell lines, which were ~ 203 and 221 µM, respectively. NMC may be used for prophylactic application either as a drop or spray since many viruses enter the human body through the mucosal lining of the nose, eyes, and lungs. Springer International Publishing 2022-11-24 2023 /pmc/articles/PMC9685086/ /pubmed/36422769 http://dx.doi.org/10.1007/s10123-022-00300-6 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research
Sorinolu, Adeola Julian
Mamun, M. Mustafa
Vadarevu, Hemapriyadarshini
Vivero-Escoto, Juan L.
Vejerano, Eric P.
Munir, Mariya
Antiviral activity of nano-monocaprin against Phi6 as a surrogate for SARS-CoV-2
title Antiviral activity of nano-monocaprin against Phi6 as a surrogate for SARS-CoV-2
title_full Antiviral activity of nano-monocaprin against Phi6 as a surrogate for SARS-CoV-2
title_fullStr Antiviral activity of nano-monocaprin against Phi6 as a surrogate for SARS-CoV-2
title_full_unstemmed Antiviral activity of nano-monocaprin against Phi6 as a surrogate for SARS-CoV-2
title_short Antiviral activity of nano-monocaprin against Phi6 as a surrogate for SARS-CoV-2
title_sort antiviral activity of nano-monocaprin against phi6 as a surrogate for sars-cov-2
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685086/
https://www.ncbi.nlm.nih.gov/pubmed/36422769
http://dx.doi.org/10.1007/s10123-022-00300-6
work_keys_str_mv AT sorinoluadeolajulian antiviralactivityofnanomonocaprinagainstphi6asasurrogateforsarscov2
AT mamunmmustafa antiviralactivityofnanomonocaprinagainstphi6asasurrogateforsarscov2
AT vadarevuhemapriyadarshini antiviralactivityofnanomonocaprinagainstphi6asasurrogateforsarscov2
AT viveroescotojuanl antiviralactivityofnanomonocaprinagainstphi6asasurrogateforsarscov2
AT vejeranoericp antiviralactivityofnanomonocaprinagainstphi6asasurrogateforsarscov2
AT munirmariya antiviralactivityofnanomonocaprinagainstphi6asasurrogateforsarscov2